Top news of the week: 31.01.2023.
Biotech CFOs eye research cuts, partnerships amid sector retrenchment: report
The report, a yearly poll of 100 financing executives by accounting and consulting firm BDO, revealed the many levers young drugmakers are pulling to conserve cash.
Veteran biotech leader George Scangos to step down as Vir CEO
The former Biogen head is retiring after taking Vir from a small startup to a publicly traded developer of infectious disease drugs. Bayer executive Marianne De Backer will succeed him.
Three VCs launch Dimension, a new firm with plans to fuel biotech’s ‘digitization’
The veteran investors see the marriage of tech and life sciences as the “largest opportunity in venture today,” said co-founder and former Lux Capital general partner Adam Goulburn.
Cooley’s 2022 Life Sciences M&A Year in Review
Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from...
These Venture Veterans Have Launched A $350 Million Fund Aimed At Digitizing Life Sciences
Dimension, which was founded by alumni of Lux Capital and Obvious Ventures, wants to focus on the intersection of life and computer sciences.
Arch Ventures-incubated clinical trials startup leaves stealth with $203M
Paradigm, a healthtech startup that has received a $203 million Series A, is creating technology to match patient records with clinical trial criteria.
A 45-year-old biotech CEO may have reduced his biological age by at least 5 years through a rigorous medical program that can cost up to $2 million a year, Bloomberg reported
Health tests and reports suggest that Bryan Johnson, 45, has the heart of a 37-year-old and gets erections like a teenager, Bloomberg reported.
Generative AI: No Humbug
In 1845, dentist Horace Wells stood before Harvard medical students and faculty, eager to demonstrate the utility of nitrous oxide – laughing gas – as a general anesthetic. Wells tried it ...